PMID- 19944969
OWN - NLM
STAT- MEDLINE
DCOM- 20091224
LR  - 20211020
IS  - 1558-1349 (Electronic)
IS  - 1042-3680 (Linking)
VI  - 21
IP  - 1
DP  - 2010 Jan
TI  - The epidermal growth factor variant III peptide vaccine for treatment of 
      malignant gliomas.
PG  - 87-93
LID - 10.1016/j.nec.2009.08.004 [doi]
AB  - Epidermal growth factor variant III (EGFRvIII) is the most common alteration of 
      the epidermal growth factor (EGF) receptor found in human tumors. It is commonly 
      expressed in glioblastoma multiforme (GBM), where it was initially identified. 
      This constitutively active mutant receptor leads to unregulated growth, survival, 
      invasion, and angiogenesis in cells that express it. EGFRvIII results from an 
      in-frame deletion of exons 2 to 7 resulting in the fusion of exon 1 to exon 8 of 
      the EGF receptor gene creating a novel glycine at the junction in the 
      extracellular amino terminal domain. The juxtaposition of ordinarily distant 
      amino acids in combination with the glycine that forms at the junction leads to a 
      novel tumor-specific epitope that would make an ideal tumor-specific target. A 
      peptide derived from the EGFRvIII junction can be used as a vaccine to prevent or 
      induce the regression of tumors. This peptide vaccine has now proceeded to phase 
      1 and 2 clinical trials where it has been highly successful and is now undergoing 
      investigation in a larger human clinical trial for patients who have newly 
      diagnosed GBM. In this article, the authors discuss the preclinical data that led 
      to the human trials and the exciting preliminary data from the clinical trials.
FAU - Li, Gordon
AU  - Li G
AD  - Department of Neurosurgery, Stanford University School of Medicine, 300 Pasteur 
      Drive, Edwards Building Room 213, Stanford, CA 94305, USA.
FAU - Mitra, Siddhartha
AU  - Mitra S
FAU - Wong, Albert J
AU  - Wong AJ
LA  - eng
GR  - R01 CA069495/CA/NCI NIH HHS/United States
GR  - R01 CA096539/CA/NCI NIH HHS/United States
GR  - R01 CA124832/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Neurosurg Clin N Am
JT  - Neurosurgery clinics of North America
JID - 9008004
RN  - 0 (Cancer Vaccines)
RN  - 0 (Vaccines, Subunit)
RN  - 0 (epidermal growth factor receptor VIII)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Animals
MH  - Brain Neoplasms/*drug therapy
MH  - Cancer Vaccines/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Drug Evaluation, Preclinical
MH  - ErbB Receptors
MH  - Glioma/*drug therapy
MH  - Humans
MH  - Immunotherapy/methods
MH  - Vaccination
MH  - Vaccines, Subunit/*therapeutic use
RF  - 45
EDAT- 2009/12/01 06:00
MHDA- 2009/12/25 06:00
CRDT- 2009/12/01 06:00
PHST- 2009/12/01 06:00 [entrez]
PHST- 2009/12/01 06:00 [pubmed]
PHST- 2009/12/25 06:00 [medline]
AID - S1042-3680(09)00074-6 [pii]
AID - 10.1016/j.nec.2009.08.004 [doi]
PST - ppublish
SO  - Neurosurg Clin N Am. 2010 Jan;21(1):87-93. doi: 10.1016/j.nec.2009.08.004.